Healthcare led the S&P sector board as money rotated out of AI and chip names: XLV +1.9%.

September PPI (8:30 ET) ran hot at +1.3% m/m and +6.3% y/y vs ~5.5% expected, a day after Wednesday's hot CPI, yet the 10-year fell ~9bp to ~5.10%.

Market data: U.S. cash close Thursday, 15 October 2026.

AstraZeneca will pay insitro $40M upfront and up to $1.46B in development and commercial milestones (~$1.5B total) to run insitro's AI target-discovery platform in MASH and cardiomyopathies, with exclusive worldwide rights to advance programs it selects. Target count and royalties were not disclosed.

Why it matters: Strip out the headline and AstraZeneca is paying under 3% of the $1.5B for a discovery option; the other $1.46B rides on programs that do not exist yet. That is cheap access to insitro's human-genetics and cell-imaging platform in two areas where AZ needs fresh biology: MASH, and cardiomyopathy after Wainua missed the primary endpoint of the CARDIO-TTRansform ATTR-CM outcomes trial this summer. It extends an AI run at AZ that already includes the Algen immunology pact, the Owkin licence and the Modella AI acquisition. insitro adds a fourth big-pharma partner after Gilead, BMS and Lilly, which validates the platform but says little about what its last disclosed raise, $400M in 2021, is worth today. Nothing here reaches the clinic for years.

Source: Endpoints

More: Fierce Biotech; BioSpace

EMA's CHMP recommended EU approval of Revolution Medicines' Rasonque (daraxonrasib), an oral RAS(ON) multi-selective inhibitor, as monotherapy for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. In Phase 3 RASolute 302 (n=500) median OS was 13.2 vs 6.7 months on chemotherapy (HR 0.40) and median PFS 7.2 vs 3.6 months (HR 0.49). The European Commission makes the final call.

Why it matters: EU clearance would complete a transatlantic launch that began with FDA approval on 26 August, on a label with no mutation restriction from a trial where 92% of patients carried a RAS G12 mutation. An OS hazard ratio of 0.40 against chemotherapy in second-line PDAC is the bar every next-wave KRAS program now gets measured against, Verastem's VS-7375 included. EMA's own summary cites the more conservative ad hoc OS cut (12.4 vs 6.7 months, HR 0.49), and tolerability gives EU payers leverage: diarrhea 63%, acneiform dermatitis 62%, stomatitis 56%. The bigger value pool is first line, where FDA granted Breakthrough Therapy designation to the chemo combination in September and RASolute 309 with zoldonrasib in G12D began dosing this month.

Source: EMA

More: Revolution Medicines

OrbiMed raised $3B across two vehicles: OrbiMed Asia Partners VI at more than $1B, its largest Asia fund, and OrbiMed Private Investments X at more than $1.9B for U.S. and European life-science venture. Both invest across biopharma, medtech and tech-enabled healthcare services.

Why it matters: The Asia number is the signal. Fund VI is roughly a third larger than Fund V's $751M, raised while China-sourced assets take a growing share of big-pharma in-licensing and the COINS Act extension still hangs over those deals. The flagship tells a flatter story: Fund X at $1.9B+ is barely above its $1.86B predecessor, so OrbiMed is scaling Asia faster than its U.S./EU venture book. Add Forbion's €2.3B close on 7 October and TCGX's $600M Asia fund on 8 October and specialist LPs are still writing checks, but into established platforms. For private biotechs that means syndicate leads with dry powder into 2027; for emerging managers it means a harder raise.

Source: Endpoints

More: Fierce Biotech

Lakefront Biotherapeutics (ex-Galapagos) sold its preclinical armed CAR-T portfolio to Armed Cell Therapeutics, a new Belgian biotech set up by former CEO Paul Stoffels, for €8M ($9M) upfront and up to $230M in milestones. — Endpoints

Osivax's nucleoprotein flu vaccine OVX836 missed its Phase 2b primary endpoint (n=2,850; 24% vaccine efficacy vs a 50% bar); it will now pursue a combination with GC Biopharma's GC FLU. — Endpoints

Lilly's post-hoc Omvoh analyses at UEG Week showed 27.7% vs 14% one-year “comprehensive disease control” in UC (LUCENT-2) and 20.4% vs 2% steroid-free deep remission in Crohn's (VIVID-1 follow-up). — Fierce Pharma

Kindeva won a $226M U.S. military contract to supply a self-injected nerve agent antidote. — Fierce Pharma

Isotope supplier NorthStar partnered with Beijing CRO Quarkmed to prepare China radiopharmaceutical filings. — Fierce Pharma

Virginia has landed at least $12.6B in commitments from three drugmakers as manufacturing onshoring picks up. — Endpoints

A CDC page backing Covid vaccination in pregnancy went live briefly, then was redirected after online backlash. — Endpoints

AstraZeneca / insitro: $40M upfront, up to $1.46B milestones, AI target discovery in MASH and cardiomyopathies; AZ takes exclusive worldwide rights to selected programs (see The Big 3). — Fierce Biotech

Lakefront (ex-Galapagos) / Armed Cell Therapeutics: preclinical armed CAR-T portfolio, €8M ($9M) upfront, up to $230M in milestones. — Fierce Biotech

OrbiMed: $3B fund close, Asia Partners VI ($1B+) and Private Investments X ($1.9B+) (fund close; see The Big 3). — Endpoints

Microbiotica: £36M ($48M) Series C first close, led by British Business Bank, joined by Tencent, IP Group, Cambridge Innovation Capital and Flerie Invest; funds Phase 2 of MB310, an oral eight-strain bacterial therapy for ulcerative colitis, after the COMPOSER-1 Phase 1b win. — PR

City Therapeutics (CTY): upsized IPO priced 11.1M shares at $18 (midpoint of $17-19; 9.7M shares at terms), ~$200M gross; Factor XI siRNA CITY-FXI in Phase 1; GS/Jefferies/Stifel/Oppenheimer; trades on Nasdaq today. — Fierce Biotech

Frazier Life Sciences Acquisition Corp. II: $75M SPAC IPO, 7.5M shares at $10, to take a biotech public by merger; Frazier's first SPAC merged with NewAmsterdam Pharma in 2022. — PR

Recursion (RXRX): $200M underwritten follow-on, 61.54M Class A shares at $3.25; Leerink/GS/MS/Evercore; closes ~16 Oct. — PR

Lancet commented on establishing cardiovascular safety for oral GLP-1 agonist orforglipron in type 2 diabetes. — Lancet

Lancet examined whether shorter hepatitis C treatment could speed elimination efforts. — Lancet